Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Clinical role
Detection, localization and characterization after the initial physician read
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Physician review of the complete examination and patient history remains necessary. Results are viewed after the initial read; this authorization does not replace clinical judgment or establish autonomous screening or DBT analysis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Standard DICOM FFDM mammograms from compatible systems; validation used standard four-view 2D images from Hologic, GE Healthcare and Siemens.
Who uses it?Intended users: Physicians interpreting screening mammograms
What does the software produce?Output: Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.
What is its most important limitation?Key limitation: Physician review of the complete examination and patient history remains necessary. Results are viewed after the initial read; this authorization does not replace clinical judgment or establish autonomous screening or DBT analysis.
Clinical takeaway. Clinical role: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Evidence takeaway. Evidence from the reviewed source record: The exact v1.1.10 standalone study is available with threshold and population context. Four stored family trial leads do not establish linkage to this release. The summary's AUC acceptance statement needs clarification.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.
Physician review of the complete examination and patient history remains necessary. Results are viewed after the initial read; this authorization does not replace clinical judgment or establish autonomous screening or DBT analysis.
The exact v1.1.10 standalone study is available with threshold and population context. Four stored family trial leads do not establish linkage to this release. The summary's AUC acceptance statement needs clarification.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact v1.1.10 standalone study is available with threshold and population context. Four stored family trial leads do not establish linkage to this release. The summary's AUC acceptance statement needs clarification.
DesignManufacturer standalone evaluation on a held-out multi-facility US FFDM dataset
PopulationAdult female screening mammography cases, Hologic/GE/Siemens acquisitions; enriched validation composition is not a routine screening prevalence estimate
Scopeexact submission
Tested versionLunit INSIGHT MMG v1.1.10
Samplen=2412
Sites28
IndependenceSponsor or vendor study
K260320
Two or three breast radiologists defined truth using clinical and pathology evidence. Printed AUC lower bound 0.896 conflicts with the claimed greater-than-0.903 criterion; no independent reader benefit for this release is inferred.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Standard DICOM FFDM mammograms from compatible systems; validation used standard four-view 2D images from Hologic, GE Healthcare and Siemens.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM mammograms are uploaded to the analysis engine; the summary identifies Secondary Capture analysis output and removal of its one-view mode.
Scope: Exact FDA submission. Exact PACS interoperability and interface configuration need local confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Current hosting model, region, hardware, latency and retention for v1.1.10 were not established by the reviewed sources.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-05 ·
Returned objects
Source context, not route validation: Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Lunit's information security page states the company is ISO/IEC 27001 certified, with ISO 13485 and MDSAP at its manufacturing site. Company-level; the page gives no scope, dates or product controls.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
The current Lunit product page describes SecondRead AI as an optional out-of-pocket breast-screening analysis program with radiologist review, training and program materials.
product family · checked 2026-09-05
No exact v1.1.10 linkage, price or payer determination; regional availability requires confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
23Fields reviewed
12Source classes checked
0Screened PubMed leads
4Screened trial leads
0Unreviewed FDA recall leads
All four stored trial titles and sponsors were screened. They are plausible Lunit family leads but metadata does not identify v1.1.10/K260320; no trial result is promoted. Full registry content and release linkage remain pending. No stored PubMed candidates. The current discovery snapshot contains 0 PubMed and 4 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor documentation, literature index, trial registry, fda decision summary, vendor product page, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
The current vendor page mentions optional out-of-pocket SecondRead AI, but gives no verified v1.1.10 price, contract unit or included services.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Lunit INSIGHT MMG reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Search results were Korean coverage news, not US coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Deployment: Not verified - checked 2026-09-05 - Exact FDA submission
Current hosting model, region, hardware, latency and retention for v1.1.10 were not established by the reviewed sources.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Vendor family program support mentions training, but the v1.1.10 curriculum, responsibilities and support term are not established.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Editorial acceptance question: verify the installed model, default operating point, supported FFDM systems and post-initial-read display sequence; supplied monitoring commitments remain unknown.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.